Abstract
There is increasing evidence that certain probiotic strains can be useful in improving human health. The use of probiotics has received attention as a natural way of restoring bodys normal microbiota, and an alternative and inexpensive way of preventing or treating infectious diseases without side effects. The best-documented clinical application of probiotics comes from trials on the treatment of gastrointestinal infections, mainly infectious diarrhoea. The enhancement of local as well as systemic immune responses by probiotics also offers new opportunities for probiotics in preventing infections at distal mucosal surfaces, such as those in the oral cavity, respiratory and urogenital tracts. The underlying mechanisms of probiotics are still unclear, but may include strengthening of the non-immunological gut barrier, interference with pathogen adhesion and growth inhibition, and the enhancement of the local mucosal immune system in the gut, as well as of the systemic immune response.
Keywords: Probiotics, Lactobacillus, Bifidobacterium, gastrointestinal, oral, respiratory, urogenital, infection
Current Pharmaceutical Design
Title: Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence
Volume: 14 Issue: 14
Author(s): K. Hatakka and M. Saxelin
Affiliation:
Keywords: Probiotics, Lactobacillus, Bifidobacterium, gastrointestinal, oral, respiratory, urogenital, infection
Abstract: There is increasing evidence that certain probiotic strains can be useful in improving human health. The use of probiotics has received attention as a natural way of restoring bodys normal microbiota, and an alternative and inexpensive way of preventing or treating infectious diseases without side effects. The best-documented clinical application of probiotics comes from trials on the treatment of gastrointestinal infections, mainly infectious diarrhoea. The enhancement of local as well as systemic immune responses by probiotics also offers new opportunities for probiotics in preventing infections at distal mucosal surfaces, such as those in the oral cavity, respiratory and urogenital tracts. The underlying mechanisms of probiotics are still unclear, but may include strengthening of the non-immunological gut barrier, interference with pathogen adhesion and growth inhibition, and the enhancement of the local mucosal immune system in the gut, as well as of the systemic immune response.
Export Options
About this article
Cite this article as:
Hatakka K. and Saxelin M., Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence, Current Pharmaceutical Design 2008; 14 (14) . https://dx.doi.org/10.2174/138161208784480162
DOI https://dx.doi.org/10.2174/138161208784480162 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pulmonary Disease in Beta-Thalassemia
Current Respiratory Medicine Reviews Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate
Current Drug Discovery Technologies Q Fever Endocarditis
Infectious Disorders - Drug Targets Development of Infection and Inflammation Targeting Compounds
Current Radiopharmaceuticals Quorum Sensing Inhibitors from the Sea: Lessons from Marine Symbiotic Relationships
Current Organic Chemistry Invasive Aspergillosis: New Insights into Disease, Diagnostic and Treatment
Current Pharmaceutical Design Neuropsychiatric Involvement in Systemic Lupus Erythematosus:Current Therapeutic Approach
Current Pharmaceutical Design Current Concepts of Immunopathogenesis, Diagnosis and Therapy in Whipples Disease
Current Medicinal Chemistry Phytochemicals as Inhibitors of Candida Biofilm
Current Pharmaceutical Design Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry Methods to Measure Target Site Penetration of Antibiotics in Critically Ill Patients
Current Clinical Pharmacology Injecting Illicit Substances Epidemic and Infective Endocarditis
Infectious Disorders - Drug Targets Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Regulating the Safety of Probiotics - The European Approach
Current Pharmaceutical Design Current Status of Molecular Imaging in Infections
Current Pharmaceutical Design Vasopressin and Terlipressin in Neonates and Children with Refractory Septic Shock
Current Drug Metabolism Methylene Blue not Contraindicated in Treating Hemodynamic Instability in Pediatric and Neonate Patients
Current Pediatric Reviews LC-MS for Simultaneous Determination of Vancomycin and Teicoplanin in Patient Plasma and its Application to Therapeutic Drug Monitoring
Current Pharmaceutical Analysis Susceptibility of Intracellular Coxiella burnetii to Antimicrobial Peptides in Mouse Fibroblast Cells
Protein & Peptide Letters Editorial [Hot topic: Infective Endocarditis (Guest Editor: Ioannis Starakis)]
Infectious Disorders - Drug Targets